id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-N-4348-0007,FDA,FDA-2025-N-4348,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act",Notice,30 Day Proposed Information Collection,2026-02-23T05:00:00Z,2026,2,2026-02-23T05:00:00Z,2026-03-26T03:59:59Z,2026-02-23T19:24:04Z,2026-03448,1,0,09000064b91d0371
FDA-2025-N-4348-0001,FDA,FDA-2025-N-4348,"Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act",Notice,60 Day Proposed Information Collection,2025-11-24T05:00:00Z,2025,11,2025-11-24T05:00:00Z,2026-01-24T04:59:59Z,2026-01-24T13:16:51Z,2025-20773,0,0,09000064b909356a